Equities Analysts Issue Forecasts for Eyegate Pharmaceuticals Inc’s FY2016 Earnings (EYEG)
Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) – Zacks Investment Research raised their FY2016 earnings per share estimates for Eyegate Pharmaceuticals in a note issued to investors on Tuesday. Zacks Investment Research analyst B. Marckx now anticipates that the firm will post earnings per share of ($1.55) for the year, up from their prior estimate of ($1.64). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ FY2017 earnings at ($0.83) EPS, FY2018 earnings at ($0.67) EPS and FY2019 earnings at ($0.77) EPS.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Eyegate Pharmaceuticals in a research report on Tuesday, October 25th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $9.20.
Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.43 on Friday. The company’s market capitalization is $12.80 million. Eyegate Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $5.10. The firm has a 50-day moving average price of $1.57 and a 200-day moving average price of $2.30.
A hedge fund recently bought a new stake in Eyegate Pharmaceuticals stock. Sabby Management LLC acquired a new position in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 386,940 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,002,000. Sabby Management LLC owned 4.64% of Eyegate Pharmaceuticals as of its most recent SEC filing.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Stock Ratings for Eyegate Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.